OncoMatch/Clinical Trials/NCT06544265
SynKIR-310 for Relapsed/Refractory B-NHL
Is NCT06544265 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies SynKIR-310 for b cell lymphoma.
Treatment: SynKIR-310 — This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: CAR-T cell therapy
Must have received prior CAR T or were unwilling/unable to receive prior CAR T.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute · Denver, Colorado
- Winship Cancer Institute of Emory University · Atlanta, Georgia
- The University of Kansas Cancer Center · Fairway, Kansas
- Rutgers Cancer Institute · New Brunswick, New Jersey
- Abramson Cancer Center of the University of Pennsylvania · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06544265 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received CAR-T cell therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify